ObsEva Ends Linzagolix Launch Plans, Casting Another Shadow Over Women's Health
The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.
You may also be interested in...
Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.